Please login to the form below

Not currently logged in
Email:
Password:

AZ's Faslodex recommended against in UK

The UK's National Institute for health and Clinical Excellence (NICE) has issued draft guidance recommending that AstraZeneca's breast cancer drug Faslodex not be used on the NHS

The UK's National Institute for health and Clinical Excellence (NICE) has issued draft guidance recommending that AstraZeneca's (AZ) breast cancer drug Faslodex (fulvestrant) not be used on the NHS.

The body, which regulates what treatments can be funded in England and Wales, claims that the drug does not represent a good use of NHS resources when used as an alternative to aromatase inhibitor therapy.

Faslodex is intended for use if anti-oestrogen treatments are no longer controlling the spread of the cancer in postmenopausal women who have locally advanced or metastatic breast cancer that is oestrogen-receptor-positive.

Commenting on the decision, Sir Andrew Dillon, chief executive of NICE, said: "After analysing the evidence comparing fulvestrant's clinical effectiveness with aromatase inhibitor therapy, our independent committee found that the estimates of overall survival and time to tumour progression were very uncertain."

There is now a consultation period until September 13, before a further review by an independent committee. Final guidance is expected in January 2012.

23rd August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

The truth is out there: Patients first
Patient centricity, patient focus, patients first – words that are on everyone’s lips these days. But what do they really mean? Where does the patient voice fit in? And what...
mHealth: The revolution will not be digital
Could mHealth, which has been growing exponentially in recent years, be the answer we have been looking for to address our population health challenge? Could mHealth save healthcare?...
Medical information in precision medicine
Global Medical Information Leader James Oughton reveals the top trends in medical information and precision medicine....

Infographics